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Modulation of macrophage polarization is required for effective tissue repair and 
regenerative therapies. Conversion of macrophages from inflammatory M1 to fibrotic M2 
phenotype could help in diseases such as chronic wound which are stuck in inflammatory 
state. During the inflammatory phase, macrophages are of the inflammatory phenotype 
(M1) and distribute pro-inflammatory cytokines including TNF-α and IL1β which are 
microbicidal and recruit/activate cells. In normal wound healing macrophages then switch 
to a fibrotic phenotype (M2) promoting wound closure by angiogenesis, and matrix 
deposition. Chronic wounds are a major biological and financial burden to both patients 
and the health care system, costing over $25 billion to Medicare annually. Natural wound 
healing proceeds through several largely overlapping phases that involve an inflammatory 
response and associated cellular migration, proliferation, matrix deposition, and tissue 
remodeling. The initial stages of the inflammatory response are dominated by neutrophils 
followed soon after by macrophages, which become prominent at the wound site. A 
sustained inflammation is an important aspect in the disruption of the normal healing 
process that can lead to a chronic condition. The chronic conditions start when the highly 
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phagocytic M1 macrophages are done removing any infected or non-functional cells, and 
any damaged matrix or foreign debris and do not differentiate into an M2 phenotype. 
Thus, inducing these sustained M1 macrophages to differentiate into an M2 phenotype 
should correct this condition, and has been shown to improve wound healing.  
We suggest simultaneously using retinoic acid (RA) and mesenchymal stem cells 
(MSCs) to promote M1 to M2 transition. RA and MSCs have both shown to promote M1 
to M2 transition, and in addition, MSCs can promote wound regeneration. We 
hypothesize that treating M1 macrophages with retinoic acid and mesenchymal stem 
cells loaded on a pullulan/gelatin scaffold will promote M1 to M2 conversion. To 
facilitate this, we developed an electrospun hydrogel consisting of 75% pullulan and 25% 
gelatin and crosslinked with 1:70 ethylene glycol diglycidyl ether (EGDE) in ethanol 
(EtOH). Pullulan was chosen due to its ability to quench reactive oxygen species and 
reduce inflammation, as well as for its excellent mechanical properties. While gelatin was 
added to provide functional motifs for cellular attachment. The scaffold composition was 
determined via FTIR. The scaffold degraded to approximately 80% after 14 days, and 
approximately 38% of the drug was released after 7 days. Scaffold nanofibers were 
determined to 328nm (±47.9) in diameter. RA and MSCs were directly loaded and used to 
treat M1 THP1 cell derived macrophages to induce polarization. qPCR shows a reduction 
of M1 markers TNFα and IL1β, and an increase of M2 marker CCL22 after 2 days of scaffold 
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Macrophages are critical immune cells involved in controlling infection, inflammation 
and disease. These cells are multifunctional and can be highly plastic, able to switch 
between phenotypic expression patterns depending on environmental ques [1]. 
Macrophages play a role in both the adaptive and innate immune system. Their role in 
the adaptive immune system involves being antigen presenting cells. In addition, their 
induction of regulatory T cells plays a role for tissue regeneration and disease prevention 
[2]. Here we will mainly focus on their role within the innate immune system, as it relates 
to their response to bacterial infection and tissue injury.  
During wound healing macrophages migrate to the site of injury from the blood as 
well as from the surrounding tissues. Macrophages initially become inflammatory to 
promote the clearance of infection and debris. They secrete matrix metalloproteinases 
(MMPs) to remove damaged cells and make way for scar formation. Normally 
macrophages contribute to disease prevention, infection removal, debris removal, tissue 
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healing and regulation, however if regulation of wound healing does not occur 
appropriately a chronic inflammatory condition can develop [3]. This would promote a 
consistent M1 phenotype for the macrophages.  
Macrophages are commonly described as one of two phenotypes inflammatory 
M1 or fibrotic/anti-inflammatory M2 [4]. Regulation between M1 and M2 phenotypes is 
critical to manage infection and disease [5]. M1 macrophages produce inflammatory 
cytokines which recruit immune cells, such a neutrophils, promoting further 
inflammation. During normal healing processes M1 macrophages are predominant to 
removing debris, infection and damaged cells. M2 macrophages down regulate 
inflammation and promote tissue deposition. Dysregulation of M1 or M2 expression has 
been associated with inflammatory diseases including chronic infection, chronic wounds 
(i.e., diabetic, pressure and venous ulcers), asthma, cancer, Parkinson’s, chronic 
obstructive pulmonary disease, atherosclerosis, Alzheimer’s disease and cancer [6]–[12]. 
This study aims to promote conversion of M1 macrophages to M2 macrophages which 
could serve as a treatment for chronic inflammatory diseases, which show high M1 
macrophage populations.  
In our project we developed an electrospun hydrogel composed of pullulan and 
gelatin, loaded with retinoic acid (RA) and adipose derived mesenchymal stem cells 
(ADMSCs) to promote M1 to M2 conversion in macrophages. Both RA and ADMSCs have 
been shown to polarize macrophages to M2 phenotype as well as fibrosis. This patch was 
designed with chronic wounds in mind taking into account studies which have used 
pullulan, gelatin, RA and MSCs in separate experiments to improve chronic wound healing 
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[13]–[16]. This is the first time each of these has been used together. Such a therapeutic 
could improve healing of chronic wounds which affect over 8.2 million patients on 
Medicare and cost over 25 billion dollars per year [17], [18].  
When macrophages arrive at the site of inflammation they are exposed to 
inflammatory stimulants such as lipopolysaccharide (LPS) and interferon gamma (IFN-γ) 
which causes polarization towards the M1 phenotype. These macrophages then further 
stimulate inflammation by releasing inflammatory cytokines including TNF-α and IL1β, as 
well as other microbicidal molecules such as MMPs. At the end of the inflammatory 
phase, M1 macrophages differentiate into M2 macrophages, which express anti-
inflammatory cytokines, including CCL18 and CCL22.  
Macrophage role in adaptive immunity also depends on their polarization. M1 
macrophages are antigen presenting cells which recruit and communicate with T helper 
Th1 cells, while M2 macrophages coordinate Th2 cell recruitment and suppress Th1 cell 
response. Macrophages play a vital role in controlling infection, disease, regeneration and 
wound healing, and by promoting M1 to M2 transition inflammatory diseases be 
ameliorated [19]. [20], [21] 
We hypothesize a novel combination of MSCs and RA loaded with electrospun 
nanofiber scaffold made of pullulan and gelatin as a therapeutic to promote M1 to M2 
induction. Research has shown that ADMSCs and RA improve M1-M2 transition and 
wound repair, however, their joint effect has not been documented [13], [14], [22], [23]. 
Pullulan was chosen because it offers good biocompatibility and anti-inflammatory 
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properties by  quenching reactive oxygen species (ROS)  [15], [24]–[26]. Gelatin has good 
biocompatibility and binding motifs for cellular adhesion, making it an ideal copolymer. 
Gelatin is extensively used in biomedical engineering and has been approved for use in 
drug delivery and wound healing [27]. After electrospinning, ethylene glycol Diglycidyl 
ether (EGDE) was used to crosslink the nanofibers. It can bind to the hydroxyl group on 
both pullulan and gelatin to improve mechanical strength and delay degradation. Pullulan 
and gelatin has been shown to be effective scaffolds for wound healing [28]–[30]. This is 
the first study which combines MSCs, RA, pullulan and gelatin. Here we verify the 
structure and composition of the scaffold using FTIR and SEM, examine degradation and 
release rate, and evaluate the potential to modulate macrophage polarity from M1 to M2 









2.1 Macrophages  
Macrophages are immune cells derived from the myeloid lineage. They are 
located throughout the body and stationed in specific tissues to help recycle dead cells 
and clean away foreign debris and material. When there is no tissue damage, 
macrophages help to recycle apoptotic cells and around 200 billion dead erythrocytes per 
day [31].  This process is known as phagocytosis, and it is locally controlled in response to 
specific ques [32]. Macrophages also regulate the inflammatory response which is part of 
the response to cell death and debris. Imbalances in the inflammatory process result in 
cell and tissue damage such as in chronic inflammatory disease [33]-[34]. 
2.1.1 Macrophage Development and Specialization 
Macrophages are replenished by bone marrow derived monocytes; however, 
tissue-specific macrophages may rely on a self-renewal process. Tissue specific 
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macrophages that self-renew originate from embryonic macrophages. Bone marrow-
derived macrophages, on the other hand, provide macrophages on demand from 
monocyte precursors. Bone marrow-derived macrophages come from hematopoietic 
stem cells, which give rise to Ly6Chi monocytes. These require CCR2 to be able to exit the 
bone marrow and enter the blood stream. Fate mapping activates important reporter 
genes to determine downstream lineage. Bone marrow monocytes can differentiate into 
many types including tumor-associated macrophages, monocyte-derived dendritic cells 
(e.g., during colitis, lung infection, etc.), effector monocytes (e.g., for colitis, peritonitis, 
liver disease), monocyte-derived macrophage (e.g., for tissue injury, such as skin, muscle, 
heart and central nervous system), and some tissue-resident macrophages (e.g., found in 
intestine, lung, mammary gland, skin, heart, osteoclasts). The tissue-resident 
macrophages derived from monocytes have a limited half-life and no self-renewal [3], 
[35]. 
2.1.2 Macrophages in Tissue 
The mononuclear phagocyte cellular system can be considered the sum total of 
responses due to mononuclear cells, such as macrophages. It is adaptable and contributes 
to both, adaptive and innate immunity. All macrophages, including tissue specific and 
bone marrow-derived, are a part of it. Tissue-specific macrophages can be identified via 
morphology, histological staining, or labeling of phagocytic particles. A common marker 
for macrophage differentiation if the F4/80 antigen which is associated with endothelial 




Macrophages have specific functions in the tissues they are localized in. For 
instance, stromal macrophages have been found to support erythropoiesis, spleen 
macrophages support cell turnover and innate and adaptive immunity, lung macrophages 
protect airways, peritoneal macrophages guard the abdominal serous cavity, and neural 
macrophages support development. Macrophages affect growth and development of 
many tissues.  [38] 
2.1.3 Macrophage Polarization 
Macrophage polarization refers to the activation of certain sets of macrophage 
genes and deactivation of others. Macrophages are very plastic cells with the ability to 
have varying gene expression. They variation in expression is in response to many signals 
such as debris, tissue trauma and infection. Activated macrophages are generally 
categorized as M1 or M2 macrophages. M1 macrophages are inflammatory in phenotype 
and has toll like receptors and interferon signaling. These are associated with 
inflammatory response such as to bacterial invasion. M2 macrophages are associated 
with fibrosis (i.e., extracellular matrix deposition) and tissue repair and regeneration. 
They also play a role in TH2 immunity. [5], [25], [39], [40] 
Macrophages are directly associated with the inflammatory response. Cellular 
environments such and expression and cytokine presentation play a large role on 
polarizing macrophages. Roles are varied in both resolving and non-resolving 
inflammation. Resolving inflammation occurs in the normal healing process in which cells 
are properly regulated and M1 macrophages turn into M2 macrophages, whereas non-
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resolving inflammation has prolonged inflammation such as what occurs in chronic 
inflammation. [5], [41] 
2.1.4 Resolving Inflammation vs Non-resolving Inflammation 
During resolving inflammation immune cells are recruited to the site of injury i to 
return tissue to homeostatic conditions. Monocytes and neutrophils arrive from the 
blood. Monocytes then differentiate into macrophages, which are then induced into an 
M1 phenotype. These then release cytokines to help promote repair and regulate healing, 
however this complex pathway is still not fully understood. When the debris and injury 
components are cleared up the monocyte-derived macrophages (MDMs) then become 
more fibrotic. Eventually most MDMs leave the site or die, while some convert properties 
to become similar to resident tissue macrophages. [5], [42] 
Non-resolving inflammation occur in diseases such as cancer, autoimmune 
diseases, and chronic inflammation and wounds. Monocytes are chronically recruited to 
the site of inflammation, increasing output of myeloid cells. [43], [44] 
2.1.5 Macrophages in Inflammation 
Macrophages play a major role in inflammation through their immunological 
response to remove foreign substances and by rapidly producing cytokines to invoke the 
inflammatory response. These cytokines have several functions; therefore, macrophages 
play multiple roles in inflammatory response. Cytokines involved in the inflammatory 
response include IL-1β, TNF-α, and IFN-γ, while those involved in the anti-inflammatory 
response include IL4, IL-13, CCL-18, CCL-22, TGF-β and VEGF [45]–[47]. Macrophages also 
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release chemokines and antimicrobial peptides when activated. Although the 
inflammatory process is aimed to be beneficial by removing foreign substances and dead 
cells, it can also cause tissue destruction. When macrophages are exposed to IFN-γ, 
cytokine production and the inflammatory response is greatly increased, often resulting 
in an increase in tissue destruction. [48]–[50] 
Macrophage expression of cytokines is a complex process and depends on 
environmental ques such as exposure to pathogen associated molecular patterns 
(PAMPs) or activation of the kinase-dependent signaling pathway. The kinase-dependent 
signaling pathway responsible for macrophages activation and cytokine production 
results in transcription of IFN-γ, NF-κB, CREB and AP-1. Macrophages respond to 
pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharides (LPS) by 
producing tumor necrosis factor (TNF) [51]. TNF further promotes release of several other 
inflammatory cytokines including interleukin 6 (IL-6), IL-12/23 and type 1 interferons. 
Lineage specific receptors which can have differing responses to these cytokines are 
uniquely represented in macrophages residing in specific tissue types. Macrophages are 
adept at promoting inflammation in response to LPS due to pattern recognition receptor 
toll-like receptor 4 (TLR4) and activation via lineage-specific transcription factors including 
PU.1 and C/EBP [52], [53]. Other transcription factors associated with TLR signaling 
include signal transducer and activator of transcription (STATs). STAT1, STAT2, STAT4, and 
STAT5 induce inflammation while STAT3 and STAT6 induce transcription of anti-
inflammatory genes. TLR signaling is also mediated by microRNA (miRNA) which are small 
strands of RNA (21-25 nucleotides in length) that act to suppress gene expression [51], 
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[54]–[56]. Dysregulation of macrophage miRNAs is seen in disease phenotypes such as 
cystic fibrosis [57]. [58] 
Inflammatory mediators modulate macrophage activity effectively turning off or 
on inflammation. As such there is much research into inhibition and promotion of these 
mediators either directly such as with gene silencing or indirectly by affecting another 
molecule upstream in their pathway. Such mediators include TNF-α, IL-1β, IL-6 and IL-12. 
TNF-α plays a central role in initiating the inflammatory cascade, and there has been some 
success targeting TNF-α with antibodies to reduce inflammation [59]–[62]. IL1 α and β are 
proinflammatory cytokines that affect many tissues and cell types and both signal through 
IL1 receptor 1. IL-1β is important for homeostatic regulation of sleep, temperature and 
digestion [63]. It has specifically been targeted due to its implication in pain, inflammation 
and autoimmune diseases such as rheumatoid arthritis, osteoarthritis, multiple sclerosis 
arthritis, Alzheimer’s disease, and inflammatory bowel disease [64]–[67]. Many drugs 
target  IL-1β or act as an antagonist against its receptors, however it is involved in 
regulation of many cells and tissue and is released from macrophages as well as many 
other cell types including mast cells and microglia, so treatments may cause adverse side 
effects [66]. [58] 
Other approaches to decrease inflammation work to generally reduce it (not just 
one cytokine) such as with nonsteroidal anti-inflammatory drugs (NSAIDs), steroids such 
as glucocorticoids, kinase inhibitors especially for janus activated kinases (JAKs), spleen 
tyrosine kinase (SYK) and mitogen-activated protein kinases (MAPKs), and receptor-
mediated inhibition to directly inhibit macrophage activation. NSAIDs inhibit 
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cyclooxygenase (COX) enzymes to reduce prostaglandin inflammation by inhibiting 
eicosanoid production and has proven helpful for osteoarthritis and cancer [68]–[71]. 
Glucocorticoids are a group of corticosteroids involved in metabolism of proteins and 
carbohydrates and is the most common treatment for many chronic inflammatory disease 
including diseases such as asthma, cancer and COPD [72]. Glucocorticoids reduce several 
inflammatory cytokines including IL-6, IL-12, TNF-α, and IL-1β [73]. Glucocorticoids can 
reduce NF-κB and AP-1 activity, protein kinase C, MAPKs, and several downstream 
inflammatory cytokines [73]–[75]. Glucocorticoids also increase anti-inflammatory 
transforming growth factor beta (TGF-β) [76]. [58] 
 
2.1.6 Macrophages in Inflammatory Disease 
Macrophages play a key role in response to pathogens, immunity and maintaining 
homeostasis during inflammation. As such they play an important role in managing 
inflammatory disease. Inflammation is caused by either a biological disorder such as 
inflammatory bowel disease (IBD), heart disease, stroke, cancer, diabetes, neurological 
disease, respiratory disease or the body’s response to a foreign object or infection. These 
inflammatory diseases account for approximately 70% of all deaths in the United States, 
and 63% worldwide according to the CDC [77]. Inflammatory disease is caused by 
excessive inflammation and macrophages which are responsible for ameliorating the 
disorder are predominantly stuck in the M1 phenotype. [77]–[79] 
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Recently there has been much interest in the development of therapeutics which 
induce an M1 to M2 transition in macrophages [7], [78], [80], [81]. Types of tissue 
engineering therapeutics include nanoparticle and patch loaded drugs. Wound patches 
could be helpful especially for skin wounds and may be an ideal application of our study. 
As inflammatory mediators, macrophages play an important role in healing normal 
wounds and play a large role in chronic wounds. During normal wound healing, genetic, 
epigenetic and molecular processes work together [82]. Macrophages direct 
inflammation, tissue remodeling and repair, and the transition into the proliferative 
phase of wound healing. However, during chronic wounds tissue is constantly destroyed. 
2.2 Skin Wounds 
The skin serves as a barrier which acts to protect against physical damage, chemical 
damage, loss of fluid, thermoregulation, and to prevent infection[83]. Layers of the skin 
include the epidermis, dermis, and subcutaneous tissue as shown in Figure 1 [84]. 
Damage can affect one to all layers of the skin and can cause serious issues even leading 
to death. Wound healing is a complex process that can be disrupted by many conditions 
such as age, sex, infection, smoking, obesity, diabetes, vascular disease,  and malnutrition 






Wound healing is an integral homeostatic process necessary to maintain barrier 
protection. It is a complex process involving many cells, notably macrophages and 
fibroblasts. Other hematopoietic and non-hematopoietic cells are recruited including 
neutrophils, natural killer cells, T cells, B cells, stem cells, epithelial cells and endothelial 
cells [87]. Macrophages are present throughout the entire wound healing process; 
however, they play the largest role during the inflammatory phase and proliferation 
phase. Macrophages digest tissue and cellular debris, regulate inflammation, the process 
conversion from inflammation to tissue deposition, and support cell proliferation [88], 
[89]. Inappropriate regulation can lead to excessive inflammation or fibrosis. 
Macrophages also promote fibroblast proliferation. Fibroblasts are important for tissue 
Figure 1.  Skin Anatomy 
From Andrews’ Diseases of the Skin: Clinical Dermatology (10th ed., p.1), by W.D. James, T.G. 
Berger, and D.M. Elston, 2006, Philadelphia: Elsevier Saunders. 
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deposition. They produce collagen, glycosaminoglycans, and help to regulate the process 
by releasing growth factors and cytokines [90]. However efficient the wound healing 
process is, it does not result in complete regeneration of the tissue and is considered a 
reparative process.  A scar is left behind preventing complete recovery of skin 
function.[91]  
2.2.1 Wound Closure 
Wound closure happens in one of three ways, primary, secondary, or delayed 
primary, depending on the given situation (Figure 2). Primary wound closure, also 
known as primary intention, occurs when the wound is small and clean. It is often caused 
by surgical incision or small clean cuts such as paper cuts. Most wounds heal by secondary 
wound closure. Secondary wound closure, also known as secondary intention, are 
rougher and require granulation tissue matrix to fill in the defect.  It takes longer than 
primary wound closure and creates more scar tissue. Delayed primary wound closure also 
known as third intention wound healing is somewhat similar to both primary and 
secondary wound healing. It occurs when a surgeon opens a wound, cleans it and leaves 
it for a few days to ensure there is no infection before closing the wound back up to heal 
via primary intention. This is performed for traumatic injuries when foreign bodies enter 





Figure 2. Wound Closure 
From Schwartz’s Principles of Surgery 9th ed, by Brunicardi FC, Andersen DK, Billiar TR, Dunn 
DL, Matthews JB, Pollock RE, 2009, McGraw-Hill. 
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Skin wounds pose a significant problem affecting all people at some time or 
another. There are many types of open skin wounds including abrasion, laceration, 
incisions, punctures, avulsion and amputation. Wounds causing damage to the full 
thickness of the skin including all three layers are the most dangerous, common examples 
include burn wounds, ulcers and chronic wounds [93].  
2.2.2 Types of Wounds 
Wounds can be considered either as acute, chronic of complicated.  
Acute Wounds 
Acute wounds heal themselves normally within 30 days. They are wounds that 
cannot be healed by primary intention. Acute wounds can occur due to a number or 
reasons such as biopsies or traumatic injury. Acute wounds can have other injuries 
associated with them (e.g., broken bone). Both exposed and internal wounds fall into this 
category [94]. 
Chronic Wounds 
These are wounds that become stalled in one or more phases of the wound 
healing process, such as the inflammatory phase. Various factors may prolong these 
stages such as hypoxia, necrosis, infection, and cytokine expression. Causes include 
pressure, arterial insufficiency, venous insufficiency, burns, age, genetic components 
and pressure. Continuous inflammation perpetuates a non-healing state. Even when 




Complicated wounds are a combination of chronic infection and tissue defect. 
The cause is due to traumatic injury, such as from an accident or surgery. The wound is 
contaminated and manifestation of infection depends on virulence, amount of 
pathogen, blood supply and patient immune system [94]. 
2.2.3 Phases of Wound Repair 
When skin is wounded it goes through four phases to repair the damage. 
Phase I: Hemostasis 
This phase is the first response to injury primarily to stop the flow of blood. This 
step occurs within a few minutes of the initial injury. Upon damage host cells release 
adenosine diphosphage prompting platelets to bind to collagen. Resident macrophages 
help to regulate clotting [95]. Glycoproteins are released resulting in platelet aggregation. 
Platelets and the coagulation cascade are activated. Platelets then release 
vasoconstrictive chemicals locally. Platelets are also responsible for formation of a fibrin 
clot and initiation of several growth factors including transforming growth factor (TGF), 
platelet derived growth factor (PDGF), fibroblast growth factor (FGF) and vascular 
endothelial growth factor (VEGF). Growth factors then recruit neutrophils, monocytes 





Phase II: Inflammation 
This stage generally lasts up to 4 days. Blood vessels become leaky allowing plasma 
and neutrophils to enter the site of inflammation. Neutrophils are considered the first line 
of immunological defense and help to phagocytose and trap infection/debris. 
Inflammatory cells including monocytes, macrophages, neutrophils and T lymphocytes 
migrate to the site and remove bacteria, dead cells, damaged tissue and foreign materials 
via phagocytosis. Monocytes migrate to the site from the blood stream and develop into 
monocyte derived macrophages (MDMs). Neutrophils have a very short half-life dying 
quickly which and worsen inflammation, however normally macrophages can help clear 
their remains. These cells also release more cytokines and growth factors to modulate the 
healing process and migration/activation of fibroblasts. The site of injury becomes warm 
and swells due to the influx of cells. Necrotic tissue, extracellular matrix and fibrin is 
broken down via matrix MMPs to set the stage for tissue deposition. MMPs are secreted 
by neutrophils, macrophages, epithelial cells and fibroblasts in response to inflammatory 
cytokines including TNF-α, IL-1, and IL-6 [96]. 
Chronic wounds and many inflammatory diseases progression of wound healing is 
stalled at this phase. This may be caused by increased bacterial burden or some 
underlying disease. [97] 
Phase III: Proliferation 
In acute wounds proliferation starts at around day 4 and lasts until around day 21. 
Macrophages, lymphocytes, angiocytes, neurocytes, fibroblasts and keratinocytes work 
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to deposit extracellular matrix and re-establish skin function. There is angiogenesis, 
collagen deposition, wound contraction and epithelialization. Macrophages help to 
regulate this phase by communing with surrounding cells via cytokines. [96] 
Phase IV: Remodeling 
The remodeling phase constitutes the realignment of collagen to improve the 
mechanical strength of the tissue. This process can take up to 2 years to finish. Fibroblasts 
are the main cells involved. Overall cell density decreases in the area while strength is 
increased. [96] 
2.2.4 Chronic Wounds 
Chronic wounds include diabetic ulcers, venous leg ulcers, and pressure ulcers and 
they are defined by ulceration lasting greater than 2 weeks. Wound healing becomes 
more difficult with age, and chronic wounds become more prevalent in the elderly 
population [98], [99]. Biofilm-infected cutaneous wounds extend the duration of the 
wound making treatment more complicated [100]. Chronic wounds become suspended 
during the inflammatory phase and are commonly accompanied by infection, continued 
neutrophil accumulation, disordered macrophage polarized in M1 phenotype, disordered 
lymphocyte function, high levels of proteases, and dysregulation of cytokines/growth 
factors with inflammatory cytokines being overexpressed [101]. 
Chronic wounds can be characterized by dysfunctional cytokine expression and 
growth factor activity [43], [102]. Increased inflammation leads to chronic expression of 
M1 type macrophages causing unique expression of growth factors and sustained 
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protease activity such as matrix metalloproteinase 2, 9 and 14 [103]. During the prolonged 
inflammation phase there are elevated levels of inflammatory cytokines including IL-1α, 
IL-1β, IL-6 and TNF-α, as well as a large presence of neutrophils [104].  
In wounds there is also elevated levels of ROS due to continued presence of 
neutrophils which release them [105]. Macrophages are able to clear neutrophils during 
normal wound healing, however since they are stuck in an M1 phenotype they continue 
to recruit more neutrophils to the wound site further exacerbating the condition [106]. 
The presence of superoxide contributes to inflammation and tissue destruction [107]–
[109].  
2.2.4.1 Current Therapies for Chronic Wound Treatment 
Treating chronic wounds is a difficult task. A thorough assessment of the wound 
and patient condition must be described first [110]. Infection poses a particular threat 
due to the ability of biofilms to evade traditional treatment, they are generally 
approached with antibiotics and/or tissue debridement [111]. Infection must be treated 
aggressively. Physicians follow the TIME protocol for wound healing, Tissue assessment, 
Infection control, Moisture management, Edge of wound management. After 
management and infection control the wound debridement is an important step to 
remove the current inflammatory environment and return the wound to more of an acute 
wound setting. Scalpel, ultrasound and/or enzymes can be used for debridement. The 
wound is then covered with some sort of wound dressing. Pressure to the wound must 
be carefully managed especially for pressure associated wounds. Offloading pressure for 
pressure ulcer healing away from the wound is important, therefore devices such as 
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braces, casts or specialty shoes may be used in addition to the wound patch.  Venous leg 
ulcers oppositely need compression to help control interstitial fluid build-up. If the wound 
is not healing, then amputation may be considered [85], [112]. 
There are several topical therapies that promote wound repair, however their 
therapeutic effect is limited. Some topical agents include antibiotics, silver, cadexomer 
iodine, honey, collagenase, saline and hydrogel loaded drugs [113]–[115]. Many dressings 
are used, such as cotton gauze, hydrocolloid dressings, hydrogel dressings, acrylic 
dressings, semipermeable film dressings, alginate dressings, hydrofiber dressings, semi-
permeable foam dressings, bioactive wound dressings and tissue based products [116]–
[118]. If the wound is serious enough, advanced therapies can be considered, such as skin 
graft or amputation. New therapies have been recently developed which focus on tissue 
engineering technologies. These include growth factor treatment, acellular skin grafts, 
skin substitutes and cellular therapies such as with fibroblasts, keratinocytes and/or stem 
cells. Therapies have also been designed to treat the oxidative stress and inflammatory 
environment of wounds such as the antioxidant drug catechin ECG which inhibits MMP-2 
and MMP-9, or activated protein C (APC) which binds to receptor endothelial protein C 
receptor (EPCR) to inhibit NFκB and reduce inflammation [104]. [85], [112] 
2.3 Electrospinning 
Electrospinning is the process by which electrostatic force is used to pull polymers 
from a liquid solution in the form of fibers. The solution evaporates and only the polymer 
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is left on the collector. This is an efficient method for producing fibers of nanometer 
diameter. Electrospinning has been developed by scientist, industrial professionals and 
entrepreneurs collectively since the early 1900s [119]. 
2.3.1 Applications of Electrospinning 
Electrospinning can be used for many applications in industry and biomedicine, due to its 
capacity to produce nanofibers. Other processes that can be used to produced nanosized 
fibers include drawing, which has been discontinued due to limited control of fiber 
dimension and scalability, self-assembly which is very complex and does not have good 
scalability or control of nanofiber size/uniformity, phase separation which is limited to 
specific polymers however again it has poor scalability or control over fiber dimension, 
and template synthesis which allows for control over fiber dimension  but also does not 
have good scalability. Electrospinning has been used for applications in filters, smart 
textiles and protective clothing, battery and capacitors, sensors, catalysts, drug delivery, 
tissue engineering, wound dressing, cosmetics and composite reinforcements, the top 
three being composite reinforcements, filters and tissue engineering [120]. 
Electrospinning offers a simple and cost-effective process to provide nanofibers which is 
both scalable and offers control over nanofiber dimension. [121] 
In industry the small fibers form a porous structure, which can be used for 
filtration, composite materials or as a membrane. Electrospinning is used to create 
composite fibers allowing multiple polymers to be easily and uniformly combined. 
Composites allow for altering uses and material properties [122]–[124]. Morphology, 
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diameter and arrangement of nanofibers can be controlled to suit the application. 
Electrospinning is commonly used to produce fibers used for tissue engineering scaffolds 
such as wound patches and scaffolds for tissue regeneration [125], [126]. Polymer 
properties must be optimized for the nanofiber application such as porosity, 
biocompatibility and tensile strength. Electrospinning of tissue engineered scaffolds can 
incorporate molecules, proteins and even live cells [127]–[130]. Fibers can also be aligned 
for applications such as nerve-tissue engineering [131]–[134]. Nanofiber scaffolds can be 
modified to optimal pore size for drug loading in the scaffold. Drugs can either be 
electrospun with the polymers or loaded afterwards. [121]   
There are several polymer and solvent combinations that can be used for 
electrospinning. A few common polymers include PLA, PCL, PLGA, PEG, PEO, and collagen. 
A few common solvents include Water, DMF, DCM, Chloroform, ethanol, and THF. 
Proteins like bovine serum albumin (BSA), DNA, RNA and growth factors can be 
incorporated into the polymer solutions and electrospun into the fibers as well. Different 
drugs can be loaded into electrospun scaffolds, including ibuprofen, ketoprofen, mefoxin, 
doxorubicin hydrochloride, fenbufen, paclitaxel, and dichloroacetate [135]–[140], [141], 
[142]. 
2.3.2 Process 
In electrospinning an electric field polarizes the solvent and causes electrostatic repulsion 
from the needle and attraction of the oppositely charged plate. There are many setups, 
one of the most common involving a horizontal plate and syringe parallel to the ground. 
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This setup will be discussed and is depicted in Figure 3. This setup consists of a single 
horizontal plate and syringe placed parallel to the ground. There are many other methods 
of performing electrospinning. Other common versions include a rotating drum to align 
nanofibers, and also a vertical plate set up in which gravity has more of an effect of the 
spinning and Taylor cone formation [143]–[145].  
 
 
Polymers are first dissolved in the solvent of choice. The solvent can affect the 
properties of the nanofibers so appropriate solvent and polymers must be chosen. Drugs 
or other materials can be added at this time to the solution. The solution is then loaded 
into a syringe and a blunt needle is attached. Needle diameter is one of the factors that 
can be adjusted to improve nanofiber diameter. Environmental conditions can be 
adjusted based on solution components (e.g., light sensitivity or temperature). The 
Figure 3.  Electrospinning Process 
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distance between the collector plate and the needle is one of the parameters affecting 
the nanofiber diameter. The flow rate setting on the syringe pump also affects the 
nanofiber diameter. A faster flow often yields a smaller diameter. The positive electrode 
is connected to the needle tip and the negative to the collector plate. The collector plate 
should be made of a conductive material. When everything is set, the syringe pump and 
power supply can be turned on. A small Taylor cone should appear, and a line should be 
visible coming from it and going towards the collector plate. The power supply voltage 
can be modified to adjust material properties. Results depend on the polymers and 
solvent being used. As weight percentage of the polymer increases in solution the critical 
voltage for fiber formation also increases. Electrospun nanofibers are often characterized 
by SEM and FTIR to confirm nanofiber morphology, diameter and composition. If beading 
occurs during the fiber formation, the flow rate should be increased to make sure the 
needle and collector are making continuous contact. If fibers form ribbons, a higher 
polymer concentration or more volatile solvent should be used. To make the nanofibers 
more porous, a more rapidly evaporating solvent should be used, and for smaller pores a 
less rapidly evaporating solvent can be used [146]–[149]. 
2.4 Polymer Comparison 
The intention behind this project is to develop a wound patch for healing chronic 
wounds. Therefore, we decided to work on converting M1 macrophages into M2 
macrophages. To this end several polymers were initially compared in Table 1. Pullulan 
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was shown to be relatively inexpensive, with good mechanical strength, easily modifiable, 
capable of quenching reactive oxygen species (ROS) and promoting neovascularization. 
Reducing ROS should help reduce inflammation and neovascularization is an important 
step in wound healing. Compared to other polymers, this seemed the better for wound 
healing. Gelatin was added to improve cellular adhesion and due to its ability to support 
wound healing by attracting fibroblasts and macrophages. Ethylene Glycol Diglycidyl 
Ether was chosen as the chemical crosslinker between the polymeric fibers due to its 
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Cross-linking is the process of chemically bonding a polymer or multiple polymers 
together and is usually done to increase the mechanical properties of the material. 
Electrospun nanofibers used in medical application are often crosslinked to prevent 
immediate degradation in moist environments [176]–[179]. Stability of the crosslinked 
product is dependent on the type of polymer, type of cross-linking agent, concentrations 
and environmental conditions, such as temperature, play a large role in the chemical 
reaction which produce the cure effect on the final product [180]. Stability of the polymer 
post-crosslinking depends on the degree of crosslinking, the stability of the crosslinker 
and of the polymer/polymers used, and environmental conditions (i.e., pH, temperature, 
mechanical trauma, etc.). Crosslinkers generally have two or more reactive groups and 
react with functional groups such as hydroxyl, carboxyl, amine and sulfhydryl. Crosslinkers 
Table 1. Polymer Comparison. 
Polymers compared are: pullulan, gelatin, chitosan, elastin, elastin like peptide (ELP), 
fibrin, alginate, hyaluronic Acid (HA), and poly ethylene glycol (PEG). Properties 
examined were: degradation, crosslinker, biocompatibility, source, chemical 




can be specific or less so in the case of photoreactive crosslinking. Crosslinking is used for 
scaffold strengthening and material immobilization (e.g., drugs or biomolecules) [181]. 
Common crosslinkers include those containing functional groups such as 
maleimide, sulfhydryl and succinimidyl esters. Sulfosuccinimidyl esters are water-soluble 
crosslinkers and are useful for crosslinking when organic solvents should not be used. The 
chemical structure of the polymer is altered due to crosslinking. This can change the 
polymers functional properties. Crosslinkers can form polymers from monomers, 
covalent bonds between polymers or ionic bonds between polymers. There are also 
cleavable crosslinkers like sulfoxides. Energy can be added to stimulate the reaction via 
heat or pressure. High-energy ionizing radiation such as from gamma radiation, x-ray, or 
electron beam can also be used to crosslink material. [182]  
Crosslinkers can be used to create polymers from monomers, to connect multiple 
polymers, proteins, or larger structures. There are physical crosslinkers and chemical 
crosslinkers. Physical crosslinking occurs by ionic interaction, crystallization, protein 
interaction, hydrogen bonds, steric complex formation, or hydrophobic interactions. 
Chemical crosslinkers synthesize polymer growth or polymer bonding. Chemical 
crosslinkers include homobifunctional crosslinkers and heterobifunctional crosslinkers. 
Homobifunctional crosslinkers have identical reactive groups and are used to affix certain 
functional groups they react with. Heterobifunctional crosslinkers have different reactive 
groups allowing conjugation of molecules with dissimilar reactive groups. Example 
crosslinkers include disuccinimidyl suberate (DSS), ethylene glycol diglycidyl ether (EGDE), 
glyoxal, silane, glutaraldehyde, and ethylene glycol dimethacrylate [183]–[190]. These 
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crosslinkers can be combined with polymers such as poly(vinyl alcohol) (PVA), 
poly(ethylene glycol), proteins, gelatin, chitosan, cellulose, polyacrylamide, and alginate 
[191]–[197]. Hydrogels are an example of crosslinked polymers that are often used in the 
biomedical industry. Electrospun fibers can also be used as hydrogels for wound dressing 
and other purposes [198]–[200].  Polymers and crosslinkers can be used in a variety of 
industries such as packaging, adhesives, textiles, food, drug delivery and tissue 
engineering. [182]  
Hydrogels are macromolecule gels constructed from chemically crosslinked 
polymer chains. They are synthesized from monomer crosslinking or by crosslinking of a 
polymer (e.g., crosslinking of electrospun nanofibers). Hydrogels can provide ideal 
conditions for drug delivery and as a scaffold for tissue engineering [201]–[206]. [182] 
2.5.1 Ethelene Glycol Diglycidyl Ether (EGDE) 
Ethylene Glycol Diglycidyl ether (EGDE) is a common crosslinking compound and 
has been used for crosslinking polysaccharides, proteins and organic molecules such as 
chitosan and gelatin [207]–[210].  Crosslinking with EGDE improves water resistance and 
mechanical properties of its target. EGDE has been effective for crosslinking gelatin 
pullulan, chitosan, lignin, DNA and PVA as reported by several authors [150], [211]–[216]. 
EGDE has been shown to have better biocompatibility than the common crosslinker 
glutaraldehyde [217]. EGDE contains two highly reactive epoxide functional groups at 
either end of the molecule. The three-member ring is a cyclical ether that is very reactive 
due to strained covalent bonds. This allows EGDE to bind with hydroxyl, carboxylic and 
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amine functional groups (Figure 4) [218]. Temperature and pH may be adjusted to 
improve crosslinking [215]. EGDE is able to react at a wide range of pHs, however citric 





 Pullulan is a polymeric exopolysaccharide commonly extracted from the yeast like 
fungus Aureobasidium pullulans. It has been gaining traction for use in tissue engineering 
due to its high biocompatibility and tissue regenerative properties. Pullulan is non-
hygroscopic, dissolves readily in water and is an FDA approved food additive that is slow 
digesting and low in calories making it ideal for food preservation. Due to its lack of 
Figure 4: Crosslinking Reaction of EGDE with Hydroxyl, Amine and Carboxyl Groups  
(Poursamar et al, 2016) [220] 
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functional groups promoting cell binding, it should form a copolymer with proteins 
providing such binding motifs, such as gelatin [28], [29], [219]. [152] 
 
2.6.1 Properties of Pullulan 
Pullulan is a linear, unbranching, amphiphilic molecule composed of 9 hydroxyl 
groups making it easily modifiable and crosslinkable such as with EGDE. It is composed of 
repeating α (1-4) maltotriosyl units (3-D-glucopyranosyl) with adjoining α(1-6)bonds 
[220]. Pullulan can reduce reactive oxygen species which can improve the inflammatory 
environment in wounds [15]. It has good mechanical properties, hydrophilic, 
hemocompatible and has good swelling ability. [155] 
2.6.2 Pullulan Production 
Pullulan is industrially produced by fermenting liquified starch from a source such 
as sucrose, glucose, soy bean oil, beet molasses and/or coconut byproduct with A. 
pullulans [221]–[223]. Besides being produced by Aureobasidium pullulans , other yeast 
and fungi also produce pullulan including Cytaria darwinii, Teloschistes flavicans, 
Rhodotorula bacarum and Cryphonectria parasitica [224]–[226], [26]. 
2.6.3 Pullulan Application 
Pullulan has proven to be an ideal polymer for applications in vascular tissue 
engineering, cartilage repair, bone tissue engineering and wound healing [227]–[231]. It 
is modifiable to form carboxymethyl pullulan and sulfated pullulan [232], [233]. Pullulan 
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has been shown to improve osteoconductivity and provide mechanical stability for bone 
and tooth repair [230]. Pullulan is an ideal polymer for wound healing due to its ability to 
protect the wound from bacterial infection, its modifiability, and ability to maintain a 
moist environment and prevent fluid loss [157], [234]–[236]. Pullulan has been used for 
drug delivery and antibiotics can be loaded into pullulan without loss in bioactivity [237]–
[239]. Pullulan can be loaded with many cell types including mesenchymal stem cells, 
macrophages, smooth muscle cells, and human endothelial cells [156], [227], [240]. 
Pullulan is shown to be effective to improve wound healing by including a copolymer such 
as gelatin and/or by incorporating of mesenchymal stem cells [154], [156].  
2.7 Gelatin 
Gelatin is a biopolymer derived from the hydrolysis of the protein collagen. Both 
collagen and gelatin are commonly used in tissue engineering. There are benefits to both. 
Both have great biocompatibility, gelatin is inexpensive and easier to work with however 
it has worst mechanical properties than collagen. Gelatin is commonly used in foods, 
cosmetics, pharmaceuticals and for biomedical applications. It is especially well known 
for its good cellular adhesion which is why it is often used as a copolymer for wound 
healing applications [241]. 
2.7.1 Properties of Gelatin 
Gelatin is a polypeptide containing 18 amino acids with large amounts of glycine, 
proline, alanine and hydroxyproline. Gelatin is water soluble however it requires initial 
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heating to at least 35oC. Alkali processed gelatin has predominantly alanine while acid 
processed gelatin is predominantly glycine. Gelatin structure is linear and characterized 
by hydroxyl groups, carboxylic groups and amino groups.  Some properties such as 
peptide chain size and organization of bonds can be altered by the manufacturing process. 
[242] 
2.7.2 Gelatin Production 
Gelatin is derived from skin and connective tissue. Commercially, gelatin is made 
from cattle bones, animal skins, and fish skin [243]. Depending on the source, gelatin is 
extracted by alkaline pretreatment or acid pretreatment resulting in gelatin with different 
properties. These processes affect the isoelectric point, pH and other properties. Gelatin 
type A (GA) which is acid pretreated has an isoelectric point of 8-9 and is positively 
charged at neutral pH, and gelatin type B which is alkaline pretreated has an isoelectric 
point of 4.8-5.4 and is negatively charged at neutral pH [244]. We used Gelatin Type A for 
our experiments. 
2.7.3 Gelatin Application 
Gelatin is use in food due primarily to its gelling and thickening properties and is 
used as a stabilizer in yogurt, and thickener in jam [245]. It is commonly used in tissue 
engineering for application in drug delivery, wound healing and tissue regeneration [153], 
[246], [247]. It is being used as a drug carrier of anticancer drugs such as curcumin, 
paclitaxel, and doxorubicin (DOX), it has been used in polymer composites to improve 
bone and skin regeneration, and it has been shown to act as an ideal wound healing 
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scaffold component for hydrogels and has been used with other cell types such as 
mesenchymal stem cells and fibroblasts in biomimetic scaffolds to facilitate healing [27], 
[248]–[258]. 
2.8 Retinoic Acid in Wound Healing 
Retinoic acid (RA) is a metabolite of vitamin A, and the most biologically active 
intermediate in the retinol metabolic pathway [259]. It can be presented in multiple 
isoforms such as the 13-cic-RA isoform, however, the all-trans isoform is the most 
common in tissue and will be the focus here. RA is produced in vivo as a signaling molecule 
for embryonic development and is known to play a role in axial patterning, neurogenesis, 
limb and organ development, and lymphoid development [260]. It is not entirely sure 
whether RA can be delivered between cells or that its’ production relies on stimulation 
through other pathways. RA transcriptionally regulates gene expression by binding to 
retinoid receptors such as RAR and RXR which are common in most cells. The effect of 
activating retinoid receptors differ depending on the cell type [261], [262]. 
In stem cells, when RA is produced it is transported via CRABP2 to the nucleus. In 
the nucleus RA binds to an RAR receptor. RAR then binds to an RXR receptor forming a 
heterodimer which binds to DNA and activates transcription. Many genes are both 
directly and indirectly regulated as a result. RAR and RXR need to be phosphorylated to 
actively bind and react to RA. Co-activators and co-repressors can bind to the RAR/RXR 
heterodimer to modulate this response [263]. 
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RA has been shown to decrease inflammation and regulate macrophages and 
mesenchymal stem cells and to promote wound healing. RA is used therapeutically to 
reduce injury and fibrosis in acute kidney injury, with studies showing M1 inflammatory 
macrophages become alternatively activated to M2 phenotype [264]. Pourjafar, et al., 
showed that pretreating MSCs with all-trans RA improves MSC viability and activity, and 
enhances overall proliferation and angiogenesis in a rat incision wound model [13]. In 
another study Abdelhamid, et al., showed that after exposing MSCs and peripheral blood 
mononuclear cells (PBMCs) to lipopolysaccharide (LPS) which stimulates an inflammation, 
treatment with RA improved viability and reduced the inflammatory response [265]. RA 
has also been shown to effectively convert M1 macrophages into M2 phenotype [266]. 
Lin, et al., showed that RA can stimulate M1 to M2 conversion, reduce inflammation and 
significantly improve wound healing; furthermore they found that M2 macrophages 
treated with RA causes activation of Arg1 which is a crucial gene for wound healing [267]. 
Overall RA decreases inflammation, improve angiogenesis, convert M1 macrophages to 
M2 macrophages and improve wound healing making it a novel therapeutic for 
inflammatory diseases such as chronic wounds. 
2.9 Mesenchymal Stem Cells in Wound Healing 
Mesenchymal stem cells (MSCs) have the ability to renew themselves and to 
differentiate into many cell types including adipocytes, chondrocytes, osteoblasts, 
myoblasts, fibroblasts and chondroblasts [268]. MSCs can be found in multiple locations 
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in the human body including bone marrow, adipose tissue, synovial tissue, and lung 
tissue. They are often isolated from bone marrow (bone marrow derived mesenchymal 
stem cells = BMSCs) or adipose tissue (adipose derived mesenchymal stem cells = 
ADMSCs) for research purposes. Adipose derived stem cells are particularly useful due to 
their ease of harvest and accessibility. MSCs help to maintain homeostasis and play a role 
in wound healing. MSC treatment has the potential for regeneration due to its ability for 
reverse remodeling, cell regulation and to differentiate into important cells at the wound 
site. They can be identified by the surface markers CD73, CD90 and CD105. MSCs have 
been shown to suppress inflammation from neutrophils, macrophages, dendritic cells, 
natural killer cells, mast cells and eosinophils [269]. 
In cutaneous wounds MSCs use paracrine signaling to increase angiogenesis, regulate 
inflammation and ECM, and enhance epithelialization and wound closure [270]. MSCs can 
signal fibroblast and keratinocytes to migrate to the wound site [271]. They are also able 
to inhibit the expression of MMPs which degrade tissue, thereby paving the way for 
extracellular matrix deposition [23], [272]. Many studies have shown that MSCs are able 
to improve chronic inflammatory disease and accelerate wound closure of chronic 
wounds [16], [28], [273]–[278]. Rustad, et al., showed that pullulan and collagen 
hydrogels loaded with MSCs induce MSCs to secrete angiogenic cytokines, promote 
pluripotency and to promote stemness factors Oct4, Sox2 and Klf4 [154]. Wound 
microenvironments can be harsh due to reactive oxygen species, inflammatory cytokines 
and cytotoxic mediators. Kosaraju, et al., showed that ADMSCs seeded on pullulan-
collagen hydrogel enhances survival of ADMSCs in the wound environment and promote 
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recruitment of circulating BMSCs [156]. Chen, et al., found that pullulan/collagen + MSC 
hydrogels could inhibit M1 macrophage expression, promote secretion of TFG-β1 and 
bFGF (known to regulate keratinocytes, fibroblasts and endothelial cells), and improved 
wound closure [279]. In conclusion, MSCs can improve healing and regeneration in 
chronic inflammatory diseases such as chronic wounds. In chronic wounds, MSCs, 
pullulan, collagen/gelatin and RA can further improve wound healing via increased 
angiogenesis, increased MSC stemness, decreased ROS, decreased MMPs and conversion 










The materials used for electrospinning were Concentrations of 200,000MW pullulan 
(Hayashibara Laboratories, Okayama, Japan) and gelatin Type A gelatin from porcine skin 
(Electron Microscopy Sciences, Hatfield, PA). The polymers were first dissolved in water 
at 20wt%. Polymer concentrations electrospun were 100% pullulan, 75% pullulan/ 25% 
gelatin, and 50% pullulan/ 50% gelatin. Solutions were heated to 50OC and magnetically 
stirred for 30min to make the polymers go into solution. The solution was then sonicated 
for 30min to get rid of bubbles. The polymer solutions were then loaded into 10mL BD 
Falcon syringes with an attached 22-gague needle attached. The sample was then loaded 
onto a syringe pump. The electrospinning process was carried out at 50oC by using a heat 
gun to maintain liquid phase of the solution. The device setup consisted of a syringe 
pump, a high voltage power supply (Information Unlimited, Inc.), and a collector plate 
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covered with non-stick aluminum foil. Pullulan/gelatin composite solutions were loaded 
in 10mL syringes and placed horizontally. The solution was expunged through a 22-gague 
blunt-end needle and fibers were collected. The high voltage power supply was set to 
37kV, the flow rate was set to 55μL/min (3ml/hr), and the distance between syringe 
needle and collector plate was set to 18cm. The scaffolds were stored at 4oC in a vacuum 




Crosslinking solutions were prepared at different ratios of EGDE to absolute ethanol. Both 
pullulan and gelatin are known to be crosslinked by EGDE. Ratios tested were 1:100, 1:50 
and 1:70 with the addition of 0.05M citric acid. Pullulan/gelatin nanofibers were 
Figure 5.  Pullulan/Gelatin Electrospinning Setup 
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immersed in crosslinking solution for 24h to crosslink. Crosslinked nanofibers were dried 
at 50oC for 24h. This is a modified protocol based on a method described by Li, et al., to 
crosslink gelatin [150]. 
3.3 Scaffold Loading 
After crosslinking with EGDE, nanofiber scaffolds were loaded with RA. Nanofiber 
scaffolds were first rinsed with PBS to remove any residue from EGDE crosslinker and then 
sterilized with UV for 1h prior to loading to prevent contamination. RA was diluting in 
EtOH, syringe filtered, and added to the sterilized scaffold, then dried. The amount or RA 
added was 5μg or 10μg per 10μg scaffold (this is equivalent to 5mg/mL or 10mg/mL RA 
in cell culture media respectively). Passage 4 ADMSCs were also loaded onto the scaffold. 
ADMSCs were incubated with the sterilized scaffold for 3 min. If both RA and ADMSCs 
were added to the same scaffold, RA was added first, dired, then the ADMSCs were 
added. 
3.4 Cell Culture 
Human Monocytic THP-1 cells (ATCC® TIB-202™, Manassas, VA) were maintained at 
Wright State University in RPMI culture medium (RPMI 1640, Life Technology, Grand 
Island, NY) containing 10 % heat inactivated FBS (GE Hyclone, Marlborough, MA). THP-1 
cells were differentiated into macrophages by incubating 24h with 200nM PMA (Cayman 
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Chemicals, Ann Arbor, MI) and supplemented with 30ng/mL GMCSF (GenScript, 
Piscataway, NJ) for macrophage growth. Using PMA is a commonly used method to 
differentiate THP1 monocytic type cells into macrophages [280]–[283], [284, p.], [285, p. 
1]. Macrophages were polarized to M1 macrophages by incubation with 100ng/mL LPS 
(eBioscience, San Diego, CA) and 100ng/ml IFN-γ (Invitrogen, Rockford, IL) and incubated 
at 37oC, 5% CO2 for 24h. Adult non-diabetic ADMSCs from Lonza were cultured to passage 
4 in MSC basal medium (ScienCell, Carlsbad, CA). In co-culture experiments, THP-1 cells 
were first differentiated in 24 well plates. After polarization, cells were washed and 
resuspended in 1mL 10 % FBS with RPMI. ADMSCs were cultured from passage 3 until 
confluent. They were then split and concentrated to 1 million cells per 10μL. 10μL of 
ADMSCs were then added to the scaffold. They were incubated on the sterile electrospun 
scaffold for 3 minutes, then loaded into transwell inserts (Corning, New York, NY). 
3.5 Reagents 
200nM PMA was used for macrophage differentiation. Macrophages were differentiated 
in RPMI, FBS and GMCSF. Macrophages were differentiated for 24h then macrophages 
were polarized. IFN-γ was used at a concentration of 100ηg/ml and LPS was used at a 
concentration of 100ηg/ml for macrophage polarization to M1 type macrophages. 
Macrophages were polarized to M1 phenotype for 24 hours then cells were washed and 
treated. Treatments include RA and PGG. RA (Sigma Aldrich, Saint Louis, MO) was 
dissolved in DMSO at 50mg/mL. Treatment of RA in culture was at 5μg/mL and 10μg/mL.  
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3.6  Scanning Electron Microscopy (SEM) 
SEM images of nanofiber scaffold were obtained using a Phenom Pro scanning electron 
microscope. Electrospun nanofibers were sputter coated with 10nm of iridium. Scaffolds 
concentrations imaged were 100% pullulan, 75% pullulan/ 25% gelatin, and 50% pullulan/ 
50% gelatin. Scaffolds were imaged with and without crosslinking with EGDE. Images are 
representative of the average. Nanofiber diameters were measured using ImageJ 
software. Diameter averages were compared statistically using JMP software. 3 images 
were taken for each sample with 20 nanofiber diameters measured for each image. 
3.7 Fourier-Transform Infrared Spectroscopy (FTIR) 
Scaffold compositions were determined by loading onto an attenuated total reflectance 
(ATR) attachment and using a Thermo Scientific Nicolet iS 50 FTIR (Thermo Fisher, 
Waltham, MA). Scaffolds were tested with and without RA. Data was plotted in Excel. 
3.8 Scaffold Degradation and Drug Release 
For degradation the scaffold was crosslinked at either 1:70 or 1:50 EGDE in EtOH. After 
crosslinking in EGDE RA dissolved in EtOH was added at either 5μg or 10μg and then 
allowed to dry. The scaffold was incubated with 1mL Ringers solution in 37oC incubator 
with shaking at 100rpm. Samples for each concentration was measured in quadruplicate. 
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The same sample was used consistently for both drug release and degradation. Ringers 
solution was collected and analyzed for RA using a spectrophotometer at 316nm. Time 
points for drug release collection was 1h, 4h, 8h, 24h, 72h, 168h. Time points for scaffold 
degradation was 1day, 3days, 7days, 14 days. For time points that coincide between drug 
release and degradation, Ringers solution was collected then scaffold was dried at 50oC 
for 24h and the weight of the contents measured. 1mL of fresh Ringers solution was then 
added and incubation was resumed. RA concentration was measure using a 
spectrophotometer at 316nm wavelength. Statistics for RA release and scaffold 
degradation were measured using two-way ANOVA. 
3.9 Live/Dead Imaging 
An Invitrogen ethidium/calcein kit (Invitrogen, Rockford, IL) was used to stain for live and 
dead cells. Ethidium penetrates damaged cell while Calcein is retained only by living cells. 
Live and dead cells were imaged using a Leica fluorescent microscope. cells have emission 
- excitation wavelengths of 495nm - 515nm for live cells, 528nm - 617nm for dead cells. 
3.10 qPCR 
M1 to M2 macrophage polarization for treatment with RA and MSC loaded electrospun 
and EGDE crosslinked pullulan/gelatin scaffold using qPCR. M1and M2 markers were 
assessed. M1 markers: TNF-α (Sinobiological, Beijing, China), IL1β (Sinobiological, Beijing, 
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China). M2 markers: CCL22 (Biomol, Pompano Beach, FL), CCL18 (GeneCopoeia, Rockville, 
MD). Macrophages were plated at 2e6 cells per well. 10μg scaffold was added to each 
transwell with RA loaded at 5μg or 10μg and/or passage 4 MSCs loaded at 1e6 cell. Cells 
were incubated for 2 days with treatment and then M1 and M2 markers expression was 
assessed. After incubation cells were washed with PBS. Trizol reagent (Invitrogen, 
Rockford, IL) was used to isolate RNA. NanoDrop 2000 spectrophotometer (Thermo 
Fisher, Waltham, MA) was used to measure RNA concentration. Approximately 300ηg of 
RNA was transcribed into cDNA using Applied Biosystems high-capacity cDNA reverse 
transcription kit (Foster City, CA). SYBR Green PCR master mix (Applied Biosystems, Foster 
City, CA) was used for qPCR setup, and StepOnePlus real time qPCR machine from Applied 
Biosystems (Applied Biosystems, Foster City, CA) performed reaction and analysis.  
Amplification reaction Setup: 95oC 5min for pre-denaturation, 50 cycles of [95 oC 20s, 60 
oC 40s, 72 oC 20s], Melt curve. GAPDH was used as control to determine relative gene 
expression. fold change was calculate using the formula: fold change = 2^- ΔΔCt. 
3.11 Statistical Analysis 
All data was compiled in Excel then transferred to JMP student edition 10 statistical 
software from SAS. JMP was used to perform t tests for nanofiber diameter and all qPCR 
assays. JMP was also used to perform two-way ANOVA on Scaffold Degradation and RA 








4.1 Scaffold Composition 
Pullulan is a linear, nonionic, water soluble exopolysaccharide composed of α-1,6-
linked maltotiose residues and produced by yeast like fungus Aureobasidium pullulans. It 
is composed of 9 hydroxyl groups making it a highly modifiable compound. Pullulan is 
useful in biomedicine because it is amenable to manipulation, non-toxic, biocompatible, 
blood compatible, non-toxic, biodegradable has antioxidant properties. It also has other 
properties such as being good mechanical strength and non-reducing and thermal 
stability. Pullulan has been FDA approved for use as a food preservative due to its slow 
digestibility and low-calorie count. Recent evidence supports pullulan as an ideal 
therapeutic target for tissue engineering and wound healing [152], [219]. 
Pullulan and gelatin scaffolds have shown promising wound healing abilities. 
Gelatin is a polypeptide derived from the hydrolysis of the collagen protein. Collagen is 
an important component of the extracellular matrix of connective tissue. It is ideal for use 
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in tissue engineering in scaffolds however it is not as easy to work with a gelatin. Gelatin 
is a good alternative to collagen, the major downside is that it loses some of its mechanical 
properties during the denaturing process, however crosslinking can improve its 
mechanical properties. Gelatin is also less immunogenic than collagen. The polypeptide 
arrangement of Gelatin provides a RGD motif which causes cellular attachment to the 
gelatin and can be very useful in scaffolds. Gelatin can also signal differentiation, and 
proliferation. Gelatin is FDA approved for use as a food additive and gelling agent as well 
as recently for tissue engineering applications such as drug delivery, wound healing, 
regeneration, as well as the food industry [27], [153], [241], [242], [257]. 
Pullulan and gelatin seem to be a good pair for wound repair, offering ROS 
quenching and cellular attachment as well as being a potential vehicle for drug and 
mesenchymal stem cell delivery. Therefore, we chose to use pullulan and gelatin as the 
base for our scaffold. Previous studies have shown that pullulan and gelatin can improve 
wound repair, and that cells such as MSCs can be loaded onto such a scaffold to promote 
improved wound healing[15], [28], [152], [153]. We decided to electrospin pullulan and 
gelatin which is an easy quick, cost effective and scalable method of creating scaffolds 
that allows tailorable nanofiber diameter size and porosity [141], [286]. This is the first-
time gelatin/pullulan nanofibers have been successfully and verifiably produced. There is 
one conference abstract describes an attempt to electrospin pullulan and gelatin, 
however this is the first time it has been chemically confirmed [287].  
After choosing our scaffold we tested the composition, degradation rate, and 
release rate of several polymer combinations. We used combinations of 75% pullulan with 
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0, 1:70 and 1:50 crosslinking as described in the methods. We also tested 50% pullulan 
with 0, 1:70 and 1:50. To characterize molecular composition FTIR was performed on all 
of these including with incorporation of 10μg of RA. As controls, RA, pullulan, and gelatin 
were each tested, gelatin and pullulan in their powder form, and RA as a KBr pellet. FTIR 
provides mostly qualitative data showing which materials were present. In each of our 
samples we confirmed the presence of pullulan, gelatin and loaded drug. In our invitro 
testing we had to choose one polymer which was 75% pullulan with 1:70 crosslinking, 
which is why in Figure 6 we show the FTIR spectrum of only that sample. The 75% pullulan 
with 1:70 crosslinking sample was decided upon based on degradation and drug release 
observed.  We had also tried using 1:100 crosslinker but it degraded to quickly and could 
be used invitro. 
FTIR analysis confirms gelatin and pullulan are both present in this scaffold (Figure 
6a). The presence of gelatin can be seen by C = O stretching of amide I at 1630 and  N-H 
bending of amide II at 1520 [288]. The presence of pullulan can be seen by for C=O 
stretching of sp3 Carbon hydrogen bond at 2900, C – O – H bending at 1340, C – O – C 
stretching at 1140, α-(1,4)-D-glucosidic bonds at 928, α configuration of α-D-
glucopyranose at 844, and α-(1,6)-D-glucosidic bonds at 755 [289], [290]. With the 
confirmation of the scaffold composition next we tested to see if the crosslinker was still 
present.  
In Figure 6b we confirmed the presence of EGDE in the scaffold. EGDE can 
chemically react with amino, carboxyl and hydroxyl functional groups. EGDE can be seen 
by the presence of carbon nitrogen bonds at 852 and 1260 as well as an increased peak 
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at 330 due to stretching of the hydroxyl group. The IR spectrum for EGDE was taken from 
the “Spectral Database for Organ Compounds” and superimposed on or graph to 
determine peak overlap. EGDE is a able to crosslink the hydroxyl groups on both pullulan 
and gelatin as depicted in figure 3 [150], [151], [218]. EGDE has two reactive epoxide 
functional groups which are highly reactive due to the strain existing in the epoxide ring.  
The detection of RA determined using FTIR to ensure RA was being loaded in the 
scaffold.  RA is a reactive metabolite of vitamin A has several developmental and cellular 
affects. RA binds to receptors in immune cell and is able to promotes differentiation of 
myeloid cells into macrophages, reduce inflammation, and convert macrophages in M1 
phenotype to M2 phenotype [14], [291]. After crosslinking the scaffold RA was added. 




















Ethylene Glycol Diglycidyl Ether from the Spectral Database for Organic Compounds 
http://sdbs.db.aist.go.jp/sdbs/cgi-bin/direct_frame_top.cgi 
b 
Figure 6: FTIR of pullulan, gelatin, and 75% pullulan/25% gelatin scaffold (a), FTIR of 
75% pullulan/25% gelatin scaffold before and after crosslinking 1:70 EGDE in EtOH 
(b), FTIR of 75% pullulan/25% gelatin scaffold crosslinked 1:70 EGDE in EtOH before 






4.2 Nanofiber Characterization 
Each of the polymer nanofiber combinations were imaged using SEM. We looked at 
100% pullulan, 75% pullulan and 50% pullulan (75% pullulan means 25% gelatin and so 
on). The nanofibers were also crosslinked with EGDE 1:70 and 1:50 as in the FTIR. The 
images shown in Figure 8 are similar visual between each sample. Nanofibers were seen 
to be randomly distributed and monomodal. Images were then analyzed using Image J to 
determine the diameter of the nanofibers as shown in Table 2. The diameter of the 
nanofibers was between 300-370nm for each of the samples. There was a significant 
increase in diameter as percentage of gelatin increased (Figure 8 a,b,c). 75% pullulan with 
1:70 crosslinking trends to have the smallest diameter, and smaller diameter size implies 




increased space for drug loading, therefore, this presented evidence that it may be a good 
polymer for drug delivery. 
 
Figure 8: SEM images of nanofibers; 100% pullulan (a), 75% pullulan/25% gelatin (b), 
50% pullulan/25% gelatin (c), 75% pullulan/25% gelatin with EGDE crosslinking 1:70 
in EtOH 1:70 (d), 50% pullulan/25% gelatin with EGDE crosslinking 1:70 in EtOH (e), 
75% pullulan/25% gelatin with EGDE crosslinking 1:50 in EtOH (f), 50% pullulan/25% 







4.3 Scaffold Degradation 
Degradation testing was performed by incubating samples with Ringers solution, 
which is an isotonic solution made of sodium chloride, potassium chloride, sodium 
bicarbonate and calcium chloride. To recapitulate physiological conditions by incubating 
samples in Ringer’s solution and incubating at 37oc with constant agitation. Ringers 
solution is relatively like body fluids. RA was also added to the scaffolds and examined to 
see if there was any noticeable effect, however there was no significant effect seen on 
any of the samples. It was observed that most of the sample degraded after the first day, 
however it slowed down considerably in the following days and weeks. The reason 




degradation was so high at the beginning and then slowed down considerably may have 
been due to decrease in surface area of the polymer. As the polymer degraded the highly 
porous scaffold may have shrunk reducing hydrolytic degradation of the polymers [292], 
[293]. When we examined the degradation via ANOVA  75% pullulan compositions had 
significantly less degradation compared to 50% pullulan compositions with a p value of 
<0.0005 that they were different. We decided to go with the polymer that degraded the 
least so that it would have a higher potential for prolonged drug delivery, therefore, we 
chose to use 75% pullulan for our invitro studies.  
 























75% 1:70 EGDE + 5ug RA
75% 1:50 EGDE + 5ug RA
75% 1:70 EGDE + 10ug RA
75% 1:50 EGDE + 10ug RA
50% 1:70 EGDE
50% 1:50 EGDE
50% 1:70 EGDE + 5ug RA
50% 1:50 EGDE + 5ug RA
50% 1:70 EGDE + 10ug RA
50% 1:50 EGDE + 10ug RA
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4.4 Drug Release 
RA release rate was examined at 1h, 2h, 4h, 8h, 1 day, 3 days and 1 week by 
collecting Ringer’s solution from the degradation test samples and testing absorbance at 
316nm.  Samples were either loaded with 5μg or 10μg of RA. Two concentrations of RA 
were loaded in the scaffolds 5μg and 10μg. The majority of RA was released within the 
first 24 hours. Comparing the samples via Two-Way ANOVA, RA is seen to have less 
release of 1:70 crosslinking than 1:50 crosslinking with a p value of <0.0001. 75% and 50% 
RA show similar release rates, so composition of pullulan to gelatin does not seem to 
affect release rate. Since RA has a lower release rate the 1:70 crosslinking we decided to 






4.5 M1 Macrophage Viability and Expression 
The inflammatory M1 phenotype causes cell death and delayed healing. Therefore, 
converting M1 macrophages into M2 may be able to ameliorate inflammatory disorders 
in which the M1 phenotype is overexpressed such as in chronic wounds. To assess 
treatment of RA and MSC loaded nanofibrous scaffold to convert M1 macrophages from 
M1 to M2 phenotype, we performed qPCR and determined M1 and M2 inflammatory 
marker expression. We chose to use THP-1 cells to derive our macrophages for our invitro 
studies. THP-1 cells are commonly used to study macrophage functions. We used a 




tradition method of using PMA to differentiate the promonocytic THP-1 cells into 
macrophages as has been well discussed in literature [4]. ThP-1 derived macrophages 
were then incubated with LPS and IFN-γ to induce M1 phenotype. Prior to doing qPCR 
with the treatments we first tested the length of time needed to incubate LPS and IFN-γ 
before M1 markers were expressed and to determine how the cells did with the 
treatment using a live/dead ethidium/calcein kit. The Viability test (Figure 11) showed a 
large increase in cells incubated for 2 or three days. qPCR however did not show any 
differences between 1, 2 or 3 days of treatment with LPS/IFNY (Figure 12 a-c). Important 
to note is that the M2 marker CCL18 was overly expressed (data not shown). We were 
using a large amount of LPS to stimulate M1 macrophage phenotype which can cause this 
to occur [4]. Since there was less cell death at day 1 we chose this for M1 polarization. 






Figure 11: Live/dead assay showing NT (a-c), 1 day of LPS/IFN-γ treatment (d-f), 2 day 
of LPS/IFN-γ treatment (g-i), 3 day of LPS/IFN-γ treatment (j-l).  live cells are depicted 
in green (a, d, g, j), dead cells are depicted in red (b, e, h, k), and merge (c, f, I, l) 
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4.6 Retinoic Acid and MSCs Promote M1 to M2 Conversion 
To investigate the ability for the RA and ADMSCs to re-polarize macrophages we 
then conducted invitro tests by incubating the macrophages with scaffolds, then assessed 
M1 and M2 expression patterns. IL1β and TNFα were the M1 makers tested, and CCl22 is 
the M2 marker examined. Macrophages are plastic cells and can switch polarity between 
M1 and M2 phenotype due to environmental factors. Both RA and MSC’s have been 
shown to modulate the response in previous research. In our study RA significantly 
decreases M1 polarity marker IL-1β, with a p value of 0.0197 (Figure 12 d-f). The 
pullulan/gelatin scaffold was able to significantly decrease all M1 markers and 
significantly increase all M2 markers.  10μg RA loaded scaffold and MSC loaded scaffold 
both have increased CCL22, while all treatments can significantly decreased IL1-β, and 
TNF-α compared to NT (Figure 8 g-i). All treatments were able to decrease inflammatory 
markers TNFα and IL-1β. Treatment with both mesenchymal stem cells and retinoic 
seemed the least effective to promote inflammatory cytokine CCL22 and there was no 
significant difference from the NT. Scaffold, scaffold with MSCs and scaffold loaded with 
RA were however able to significantly improve CCL22 expression. Perhaps RA is 
interacting in a way with MSCs that causes a reduction in CCL22 expression. This study 
reveals modulation of macrophages to M2 phenotype which could promote alleviation of 
several diseases. Future studies should examine the effect of these different 










In summary, electrospun scaffolds composed of pullulan and gelatin nanofibers 
were successfully fabricated and crosslinked with EGDE, and loaded with RA. This work 
demonstrates the ability of RA, MSCs and the scaffold by itself to induce a shift from a M1 
into an M2 phenotype in activated macrophages. Inflammatory markers IL1β and TNFα 
were decreased in all samples. All cells treated with RA and the scaffold containing MSCs 
were able to increase the M2 marker CCL22. MSCs and RA treated wells however did not 
have significantly improved CCL22. Further examination should be done to determine the 
reason why there was a CCL22 decrease in cells treated with both RA and MSCs. These 
tests verify the feasibility of combining this 75% pullulan and 25% gelatin electrospun 
scaffold with RA and MSCs to convert M1 macrophages into M2 phenotype, thus having 
potentially as novel therapeutic to reduce inflammatory diseases such as chronic wounds. 
 
Figure 12: qPCR of 1 day, 2 days and 3 days treatment of macrophages with 100ng 
M1 to M2 transitioning effect of 100ηg/mL LPS and 100 ηg/mL IFN-γ (a-c), qPCR of 
RA in vitro on M1 to M2 transition (d-f), qPCR of scaffolds loaded with RA and/or 
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